stockrowLiquidia Corporation
LQDA Healthcare Drug Manufacturers Specialty & Generic
Liquidia Corporation’s revenue for fiscal 2025 (year ended December 2025) was $158.3 million, up 1,031.2% from fiscal 2024.
- Revenue
- +1,842.7%
- EPS
- +271.4%
- Free cash flow
- +270.2%
- Total debt
- −9.04%
Quarter to June 2026, against a year earlier
Follow LQDA
Alert me
Liquidia Corporation (LQDA) Revenue
Liquidia Corporation's revenue for fiscal 2025 was $158.3M, up 1,031.2% from $14.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was $450.9M. Over the past ten years it has ranged from $739.6K (fiscal 2020) to $158.3M (fiscal 2025) — the current reading is the highest in ten years. Liquidia Corporation ranks 29th of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $158.3M | 1,031.18% |
| FY2024 | $14.0M | (19.97%) |
| FY2023 | $17.5M | 9.75% |
| FY2022 | $15.9M | 23.98% |
| FY2021 | $12.9M | 1,637.83% |
| FY2020 | $739.6K | (90.84%) |
| FY2019 | $8.1M | 198.19% |
| FY2018 | $2.7M | (62.70%) |
| FY2017 | $7.3M | 0.00% |
| FY2017 | $7.3M | (45.09%) |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $171.7M | 29.21% |
| Mar 2026 | $132.9M | 44.39% |
| Dec 2025 | $92.0M | 69.34% |
| Sep 2025 | $54.3M | 514.94% |
| 25 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $10.1B |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $3.2B |
| HIMS Hims & Hers Health, Inc. compare | $2.6B |
| LNTH Lantheus Holdings, Inc. compare | $1.6B |
| SUPN Indivior Pharmaceuticals Inc. compare | $1.4B |
| PBH Prestige Consumer Healthcare Inc. compare | $1.2B |
| LQDA Liquidia Corporation | $450.9M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | $87.4M |
| RGC Regencell Bioscience Holdings Limited compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on LQDA
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement